CGEM News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CG

Mkt Cap

$830.5M

Volume

942.89K

Next Earnings

November 5th

Loading chart

CG

CGEMCullinan Therapeutics, Inc. Common Stock

CGEM

Pay with—

Available Balance0.00

CG

Mkt Cap

$832.1M

Volume

942.89K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review ProgramCullinan Therapeutics announced the initiation of a New Drug Application (NDA) submission to the FDA for zipalertinib in combination with platinum-based chemotherapy for treating previously untreated EGFR exon 20 insertion NSCLC. The Phase 3 REZILIENT3 trial met its primary endpoint, demonstrating statistically significant improvement in median progression-free survival. The NDA submission is expected to be completed by year-end 2026 under the FDA's Real-Time Oncology Review program.GlobeNewswire Inc. · Oct 1, 2026

Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation ForumCullinan Therapeutics announced that its CEO Nadim Ahmed and Chief Medical Officer Jeffrey Jones will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24, 2026. The company is a clinical-stage biopharmaceutical firm developing disease-modifying T cell engagers for autoimmune diseases and cancer.GlobeNewswire Inc. · Sep 21, 2026

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung CancerCullinan Therapeutics announced it will host a virtual event on September 14, 2026, to discuss Phase 3 REZILIENT3 trial results for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC. The trial met its primary endpoint of progression-free survival at the planned interim analysis, with results to be presented at the IASLC 2026 World Conference on Lung Cancer.GlobeNewswire Inc. · Sep 10, 2026

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 CongressCullinan Therapeutics announced positive Phase 1 clinical data for CLN-978, a CD19xCD3 T cell engager, showing clinical benefit including remissions in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following single target doses. The drug demonstrated deep, dose-dependent B cell depletion with a favorable safety profile. The company will present additional data and host an Immunology Day on June 10 to discuss CLN-978 and initial data for velinotamig, a BCMAxCD3 T cell engager.GlobeNewswire Inc. · Jun 6, 2026

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 CongressCullinan Therapeutics announced that initial clinical data from Phase 1 studies of CLN-978, a CD19xCD3 T cell engager, will be presented at EULAR 2026 Congress in June. The data shows favorable safety profiles, robust B cell depletion, and early promising clinical activity in patients with treatment-refractory rheumatoid arthritis and systemic lupus erythematosus.GlobeNewswire Inc. · May 18, 2026

Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025Cullinan Therapeutics presented preclinical data for CLN-978, a novel CD19xCD3 bispecific T cell engager, demonstrating potential for B cell depletion across multiple autoimmune diseases like rheumatoid arthritis, Sjögren's disease, and systemic lupus erythematosus.GlobeNewswire Inc. · Oct 25, 2025

Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation ForumCullinan Therapeutics will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum, presenting insights into their clinical-stage therapeutic assets targeting autoimmune diseases and cancer.GlobeNewswire Inc. · Sep 12, 2025

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsCullinan Therapeutics announced ongoing clinical trials for CLN-978 and velinotamig in autoimmune diseases, shared zipalertinib oncology results, and appointed two new board members while maintaining a strong cash position of $510.9 million.GlobeNewswire Inc. · Aug 7, 2025

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid ArthritisCullinan Therapeutics received approval from the European Medicines Agency to initiate a Phase 1 trial of its bispecific CD19 T cell engager CLN-978 in patients with rheumatoid arthritis. The trial will be conducted at research institutions in Germany and Italy, and CLN-978 is also being studied for systemic lupus erythematosus.GlobeNewswire Inc. · Apr 16, 2025

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsCullinan Therapeutics reported progress in its pipeline, including initial clinical data for CLN-978 in Systemic Lupus Erythematosus expected in Q4 2025 and positive results from the pivotal Phase 2b study of zipalertinib. The company ended 2024 with $606.9 million in cash, providing runway into 2028.GlobeNewswire Inc. · Feb 27, 2025

to start trading

CG

CGEMCullinan Therapeutics, Inc. Common Stock

CGEM

Pay with—

Available Balance0.00

Your PositionYou don't own any CGEM yet.

Related Tickers

Earnings